Alcon Inc. announced on Tuesday that it has lifted its bid for STAAR Surgical to $1.6 billion, valuing the ophthalmic device maker at $30.75 per share in cash. The move follows a prior agreement to acquire STAAR and reflects Alcon’s intent to broaden its surgical portfolio, particularly in phakic intra‑ocular lenses and refractive surgery. The increased offer underscores Alcon’s strategy to deepen its market presence and leverage synergies between its existing surgical ecosystem and STAAR’s implantable lens technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.